ArticlePCN reports : psychiatry and clinical neurosciences2026
Valbenazine induced acute parkinsonism in a patient with alcohol use disorder and central pontine myelinolysis.
Article in PCN reports : psychiatry and clinical neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Valbenazine induced acute parkinsonism in a patient with alcohol use disorder and central pontine myelinolysis.PCN reports : psychiatry and clinical neurosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Valbenazine is used to treat dyskinesia and is generally associated with limited side effects; however, a few cases with the adverse effect of parkinsonism are reported in the literature. In this study, we report a case of valbenazine-induced acute parkinsonism. Case Presentation: The patient was a 60-year-old male who suffered from depression and alcohol use disorder. When he was 50 years old, he was diagnosed with Wernicke's encephalopathy, central pontine myelinolysis-induced parkinsonism, and dyskinesia. After remission, dyskinesia persisted and was diagnosed as tardive dyskinesia. The patient was treated with tetrabenazine and valbenazine at different times, and only valbenazine treatment induced acute parkinsonism. Conclusion: Valbenazine can cause acute parkinsonism, even in patients who have previously tolerated tetrabenazine, and especially in those with underlying basal ganglia lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.